Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | DR-01 |
| Synonyms | |
| Therapy Description |
ADR-01 is a non-fucosylated monoclonal antibody that targets an undisclosed cell surface receptor on cytotoxic cells, potentially leading to antitumor activity (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| DR-01 | DR01|DR 01 | ADR-01 is a non-fucosylated monoclonal antibody that targets an undisclosed cell surface receptor on cytotoxic cells, potentially leading to antitumor activity (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05475925 | Phase Ib/II | DR-01 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | Recruiting | USA | ITA | FRA | ESP | DEU | AUS | 3 |